Tianda Pharmaceuticals Posts Wider 2025 Loss on Goodwill Impairment Despite Lower Expenses

The latest update is out from Tianda Pharmaceuticals Ltd. ( (HK:0455) ).

Tianda Pharmaceuticals reported 2025 revenue of HK$322.9 million, slightly down from HK$329.9 million a year earlier, as the group maintained gross profit of HK$133.3 million but faced higher cost of sales. The company continues to operate across its established pharmaceutical segments, with spending on research and development reduced compared with 2024 and administrative and selling expenses also trimmed.

The group’s net loss widened to HK$70.3 million from HK$61.4 million, driven by a sharp increase in goodwill impairment charges and ongoing finance costs despite lower operating expenses. Total comprehensive loss narrowed to HK$49.5 million from HK$80.7 million, helped by positive exchange differences on translation, signaling some balance sheet relief even as core profitability remains under pressure for shareholders and creditors.

The most recent analyst rating on (HK:0455) stock is a Hold with a HK$0.10 price target. To see the full list of analyst forecasts on Tianda Pharmaceuticals Ltd. stock, see the HK:0455 Stock Forecast page.

More about Tianda Pharmaceuticals Ltd.

Tianda Pharmaceuticals Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands. The group is engaged in the development, manufacture and sale of pharmaceutical products, with a focus on healthcare markets served through its subsidiaries in Mainland China and other regions.

Average Trading Volume: 108,333

Technical Sentiment Signal: Sell

Current Market Cap: HK$208.6M

For a thorough assessment of 0455 stock, go to TipRanks’ Stock Analysis page.